---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-011145"
form_type: "8-K"
ticker: "HRGN"
cik: "0001563665"
company_name: "Harvard Apparatus Regenerative Technology, Inc."
filed_at: "2023-04-06T23:59:59+00:00"
generated_at: "2026-06-17T05:08:47.776524+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biostage raises ~$6M via private placement of 1M shares at $6.00; preferred stock converted

## Summary
- Gross proceeds ~$6M from sale of 1,000,967 shares at $6.00/share; $3.6M received by Apr 5, 2023.
- Funds to accelerate clinical trial of Biostage Esophageal Implant (BEI) for esophageal cancer/injury.
- All Series E Preferred Stock plus accrued dividends will convert to ~675,000 common shares at $6.00, eliminating Series E.
- FDA approved 10-patient Phase 1/2 trial for BEI; potential expansion to pediatric and bronchial indications.

## SEC filing metadata
- accession: 0001493152-23-011145
- form_type: 8-K
- ticker: HRGN
- cik: 0001563665
- company_name: Harvard Apparatus Regenerative Technology, Inc.
- filed_at: 2023-04-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563665/000149315223011145/0001493152-23-011145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563665/000149315223011145/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-011145
- JSON: https://secwatch.observer/filing/0001493152-23-011145.json
- Plain text: https://secwatch.observer/filing/0001493152-23-011145.txt

## Key facts
- Material Agreements
  Harvard Apparatus Regenerative Technology, Inc. entered into Securities Purchase Agreements with certain investors valued at $6 million (effective 2023-03-31).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain investors
  - Value: $6 million
  - Effective: 2023-03-31
  source text: On March 31, 2023, Biostage, Inc. (the “Company”) entered into Securities Purchase Agreements (each a “Purchase Agreement”) with certain investors (the “Investors”) pursuant to which the Investors agreed to purchase in a private placement an aggregate of 1,000,967 shares of common stock for the aggregate purchase price of $6 million and a purchase price per unit of $6.00 (the “Private Placement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563665/000149315223011145/0001493152-23-011145-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.